| Mrs Stacey Duran Shetty, MSN, RN-BC, NP-C | |
|
1 Valley Health Plz, Paramus, NJ 07652-3628 | |
| (201) 634-5313 | |
| Not Available |
| Full Name | Mrs Stacey Duran Shetty |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1 Valley Health Plz, Paramus, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164007936 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 26NJ01097500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Valley Hospital | Ridgewood, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Physician Services Pc | 3577857333 | 402 |
News Archive
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.
Alzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company's operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.
Full implementation of the Affordable Care Act's (ACA) national health insurance expansion could result in many more discretionary surgical procedures in the next few years based on how utilization changed after an earlier insurance reform in Massachusetts.
› Verified 5 days ago
| Entity Name | Valley Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467815928 PECOS PAC ID: 3577857333 Enrollment ID: O20160802002824 |
News Archive
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.
Alzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company's operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.
Full implementation of the Affordable Care Act's (ACA) national health insurance expansion could result in many more discretionary surgical procedures in the next few years based on how utilization changed after an earlier insurance reform in Massachusetts.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Stacey Duran Shetty, MSN, RN-BC, NP-C 1 Valley Health Plz, Paramus, NJ 07652-3628 Ph: () - | Mrs Stacey Duran Shetty, MSN, RN-BC, NP-C 1 Valley Health Plz, Paramus, NJ 07652-3628 Ph: (201) 634-5313 |
News Archive
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.
Alzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company's operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.
Full implementation of the Affordable Care Act's (ACA) national health insurance expansion could result in many more discretionary surgical procedures in the next few years based on how utilization changed after an earlier insurance reform in Massachusetts.
› Verified 5 days ago
Yongsoon Ko, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 230 E. Ridgewood Ave, Bergen Regional Medical Center, Paramus, NJ 07652 Phone: 201-207-9557 Fax: 201-784-1136 | |
Renee Barnes, APN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 140 E Ridgewood Ave Ste 415s, Paramus, NJ 07652 Phone: 615-673-4455 Fax: 615-432-4651 | |
Mrs. Althea Doreen Brown, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 230 E Ridgewood Ave, Paramus, NJ 07652 Phone: 201-967-4000 | |
Manjinder Kaur, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 230 E Ridgewood Ave, Paramus, NJ 07652 Phone: 201-212-3111 | |
Bernard Favarato Perutti, AGPCNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 90 W Ridgewood Ave, Paramus, NJ 07652 Phone: 201-652-1950 | |
Mrs. Catherine Kim, PMHNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 Forest Ave, Paramus, NJ 07652 Phone: 201-490-5158 | |
Elizabeth Heydt, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1 Sears Dr, Paramus, NJ 07652 Phone: 201-830-2287 |